nodes	percent_of_prediction	percent_of_DWPC	metapath
Naproxen—migraine—Prednisone—psoriasis	0.195	0.508	CpDpCtD
Naproxen—osteoarthritis—Prednisone—psoriasis	0.189	0.492	CpDpCtD
Naproxen—UGT2B7—Mycophenolic acid—psoriasis	0.057	0.127	CbGbCtD
Naproxen—UGT1A1—Mycophenolic acid—psoriasis	0.0493	0.11	CbGbCtD
Naproxen—UGT2B7—Mycophenolate mofetil—psoriasis	0.0319	0.0711	CbGbCtD
Naproxen—UGT1A1—Mycophenolate mofetil—psoriasis	0.0275	0.0614	CbGbCtD
Naproxen—ALB—Acitretin—psoriasis	0.0223	0.0497	CbGbCtD
Naproxen—CYP2C8—Tazarotene—psoriasis	0.0218	0.0486	CbGbCtD
Naproxen—CYP1A2—Clobetasol propionate—psoriasis	0.0207	0.0462	CbGbCtD
Naproxen—SLCO1A2—Prednisolone—psoriasis	0.0171	0.0382	CbGbCtD
Naproxen—PTGS2—Triamcinolone—psoriasis	0.0166	0.0369	CbGbCtD
Naproxen—SLCO1A2—Hydrocortisone—psoriasis	0.0162	0.0362	CbGbCtD
Naproxen—SLCO1A2—Prednisone—psoriasis	0.0162	0.036	CbGbCtD
Naproxen—SLCO1A2—Cyclosporine—psoriasis	0.0153	0.0342	CbGbCtD
Naproxen—PTGS2—Betamethasone—psoriasis	0.0142	0.0317	CbGbCtD
Naproxen—CYP1A2—Methoxsalen—psoriasis	0.0109	0.0243	CbGbCtD
Naproxen—ALB—Mycophenolate mofetil—psoriasis	0.0104	0.0233	CbGbCtD
Naproxen—SLCO1A2—Dexamethasone—psoriasis	0.0101	0.0225	CbGbCtD
Naproxen—CYP2C8—Cholecalciferol—psoriasis	0.0093	0.0208	CbGbCtD
Naproxen—SLC22A6—Cyclosporine—psoriasis	0.00929	0.0207	CbGbCtD
Naproxen—ALB—Prednisone—psoriasis	0.00835	0.0186	CbGbCtD
Naproxen—PTGS2—Dexamethasone—psoriasis	0.00826	0.0184	CbGbCtD
Naproxen—SLCO1A2—Methotrexate—psoriasis	0.0081	0.0181	CbGbCtD
Naproxen—CYP2C8—Mycophenolate mofetil—psoriasis	0.00807	0.018	CbGbCtD
Naproxen—CYP2C9—Cholecalciferol—psoriasis	0.00649	0.0145	CbGbCtD
Naproxen—CYP2C8—Hydrocortisone—psoriasis	0.00647	0.0144	CbGbCtD
Naproxen—CYP2C8—Cyclosporine—psoriasis	0.00611	0.0136	CbGbCtD
Naproxen—SLC22A6—Methotrexate—psoriasis	0.00492	0.011	CbGbCtD
Naproxen—CYP2C9—Cyclosporine—psoriasis	0.00426	0.00951	CbGbCtD
Naproxen—ALB—Methotrexate—psoriasis	0.00419	0.00934	CbGbCtD
Naproxen—CYP2C8—Dexamethasone—psoriasis	0.00403	0.00898	CbGbCtD
Naproxen—CYP2C9—Dexamethasone—psoriasis	0.00281	0.00627	CbGbCtD
Naproxen—Indomethacin—CXCL8—psoriasis	0.000556	0.262	CrCbGaD
Naproxen—Ketoprofen—CXCL8—psoriasis	0.000445	0.209	CrCbGaD
Naproxen—Ibuprofen—CXCL8—psoriasis	0.000438	0.206	CrCbGaD
Naproxen—PTGS2—Fluocinonide—Clobetasol propionate—psoriasis	0.000404	0.157	CbGdCrCtD
Naproxen—Indomethacin—PPARG—psoriasis	0.000384	0.181	CrCbGaD
Naproxen—PTGS2—Fluocinonide—Beclomethasone—psoriasis	0.000324	0.126	CbGdCrCtD
Naproxen—PTGS2—Fluocinonide—Fluocinolone Acetonide—psoriasis	0.000315	0.122	CbGdCrCtD
Naproxen—Ibuprofen—PPARG—psoriasis	0.000302	0.142	CrCbGaD
Naproxen—PTGS2—Fluticasone Propionate—Clobetasol propionate—psoriasis	0.000244	0.0948	CbGdCrCtD
Naproxen—PTGS2—Fluticasone Propionate—Fluocinonide—psoriasis	0.000195	0.076	CbGdCrCtD
Naproxen—PTGS2—Fluticasone Propionate—Beclomethasone—psoriasis	0.000195	0.076	CbGdCrCtD
Naproxen—PTGS2—Fluticasone Propionate—Fluocinolone Acetonide—psoriasis	0.00019	0.0738	CbGdCrCtD
Naproxen—PTGS2—Fluocinonide—Dexamethasone—psoriasis	0.000148	0.0574	CbGdCrCtD
Naproxen—PTGS2—Fluocinonide—Betamethasone—psoriasis	0.000148	0.0574	CbGdCrCtD
Naproxen—PTGS2—Fluocinonide—Triamcinolone—psoriasis	0.000144	0.0561	CbGdCrCtD
Naproxen—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—psoriasis	9.27e-05	0.0112	CbGpPWpGaD
Naproxen—PTGS2—Fluticasone Propionate—Dexamethasone—psoriasis	8.91e-05	0.0346	CbGdCrCtD
Naproxen—PTGS2—Fluticasone Propionate—Betamethasone—psoriasis	8.91e-05	0.0346	CbGdCrCtD
Naproxen—PTGS2—Overview of nanoparticle effects—CRP—psoriasis	8.86e-05	0.0107	CbGpPWpGaD
Naproxen—PTGS2—Fluticasone Propionate—Triamcinolone—psoriasis	8.7e-05	0.0338	CbGdCrCtD
Naproxen—ALB—HDL-mediated lipid transport—APOE—psoriasis	8.48e-05	0.0102	CbGpPWpGaD
Naproxen—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	8.38e-05	0.0101	CbGpPWpGaD
Naproxen—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	8.27e-05	0.00996	CbGpPWpGaD
Naproxen—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	8.04e-05	0.00968	CbGpPWpGaD
Naproxen—PTGS1—Biological oxidations—CYP2S1—psoriasis	8.04e-05	0.00967	CbGpPWpGaD
Naproxen—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	7.95e-05	0.00957	CbGpPWpGaD
Naproxen—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL4—psoriasis	7.31e-05	0.0088	CbGpPWpGaD
Naproxen—PTGS1—Overview of nanoparticle effects—CXCL8—psoriasis	7.26e-05	0.00874	CbGpPWpGaD
Naproxen—AKR1C3—Diseases associated with visual transduction—APOE—psoriasis	6.93e-05	0.00834	CbGpPWpGaD
Naproxen—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	6.8e-05	0.00818	CbGpPWpGaD
Naproxen—UGT2B7—NRF2 pathway—TGFA—psoriasis	6.75e-05	0.00813	CbGpPWpGaD
Naproxen—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—psoriasis	6.15e-05	0.0074	CbGpPWpGaD
Naproxen—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—psoriasis	5.92e-05	0.00713	CbGpPWpGaD
Naproxen—PTGS2—Overview of nanoparticle effects—CXCL8—psoriasis	5.76e-05	0.00694	CbGpPWpGaD
Naproxen—UGT1A1—NRF2 pathway—TGFA—psoriasis	5.49e-05	0.00661	CbGpPWpGaD
Naproxen—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—psoriasis	5.37e-05	0.00647	CbGpPWpGaD
Naproxen—CYP2C8—Biological oxidations—CYP2S1—psoriasis	5.19e-05	0.00625	CbGpPWpGaD
Naproxen—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	5.12e-05	0.00616	CbGpPWpGaD
Naproxen—PTGS1—Overview of nanoparticle effects—TNF—psoriasis	5.05e-05	0.00609	CbGpPWpGaD
Naproxen—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—psoriasis	4.96e-05	0.00597	CbGpPWpGaD
Naproxen—ALB—Lipoprotein metabolism—APOE—psoriasis	4.87e-05	0.00586	CbGpPWpGaD
Naproxen—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—psoriasis	4.73e-05	0.00569	CbGpPWpGaD
Naproxen—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	4.72e-05	0.00569	CbGpPWpGaD
Naproxen—PTGS2—S1P1 pathway—VEGFA—psoriasis	4.68e-05	0.00564	CbGpPWpGaD
Naproxen—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	4.51e-05	0.00543	CbGpPWpGaD
Naproxen—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—psoriasis	4.42e-05	0.00532	CbGpPWpGaD
Naproxen—CYP2C9—Biological oxidations—CYP2S1—psoriasis	4.22e-05	0.00509	CbGpPWpGaD
Naproxen—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	4.17e-05	0.00502	CbGpPWpGaD
Naproxen—PTGS1—Selenium Micronutrient Network—CAT—psoriasis	4.13e-05	0.00497	CbGpPWpGaD
Naproxen—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	4.11e-05	0.00495	CbGpPWpGaD
Naproxen—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	4.08e-05	0.00491	CbGpPWpGaD
Naproxen—PTGS1—Overview of nanoparticle effects—IL6—psoriasis	4.08e-05	0.00491	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	4.02e-05	0.00484	CbGpPWpGaD
Naproxen—PTGS2—Overview of nanoparticle effects—TNF—psoriasis	4.01e-05	0.00483	CbGpPWpGaD
Naproxen—ALB—Hemostasis—SERPINB8—psoriasis	3.97e-05	0.00478	CbGpPWpGaD
Naproxen—SLCO1A2—SLC-mediated transmembrane transport—CP—psoriasis	3.89e-05	0.00468	CbGpPWpGaD
Naproxen—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	3.85e-05	0.00464	CbGpPWpGaD
Naproxen—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—psoriasis	3.82e-05	0.0046	CbGpPWpGaD
Naproxen—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—psoriasis	3.79e-05	0.00457	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	3.73e-05	0.00449	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—NDUFA5—psoriasis	3.71e-05	0.00447	CbGpPWpGaD
Naproxen—SLC22A6—SLC-mediated transmembrane transport—CP—psoriasis	3.65e-05	0.0044	CbGpPWpGaD
Naproxen—CYP1A2—Biological oxidations—CYP2S1—psoriasis	3.61e-05	0.00435	CbGpPWpGaD
Naproxen—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	3.56e-05	0.00429	CbGpPWpGaD
Naproxen—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	3.55e-05	0.00428	CbGpPWpGaD
Naproxen—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	3.5e-05	0.00421	CbGpPWpGaD
Naproxen—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—psoriasis	3.48e-05	0.0042	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.46e-05	0.00417	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—CAT—psoriasis	3.34e-05	0.00402	CbGpPWpGaD
Naproxen—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—psoriasis	3.29e-05	0.00396	CbGpPWpGaD
Naproxen—PTGS1—Selenium Micronutrient Network—CRP—psoriasis	3.28e-05	0.00394	CbGpPWpGaD
Naproxen—PTGS2—Selenium Micronutrient Network—CAT—psoriasis	3.28e-05	0.00394	CbGpPWpGaD
Naproxen—ALB—Vitamin B12 Metabolism—CRP—psoriasis	3.25e-05	0.00392	CbGpPWpGaD
Naproxen—PTGS2—Overview of nanoparticle effects—IL6—psoriasis	3.24e-05	0.0039	CbGpPWpGaD
Naproxen—ALB—Lipid and lipoprotein metabolism—APOE—psoriasis	3.24e-05	0.0039	CbGpPWpGaD
Naproxen—ALB—Vitamin B12 Metabolism—APOE—psoriasis	3.19e-05	0.00384	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—CYP2S1—psoriasis	3.16e-05	0.0038	CbGpPWpGaD
Naproxen—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	3.14e-05	0.00378	CbGpPWpGaD
Naproxen—CYP1A2—Tryptophan metabolism—CAT—psoriasis	3.11e-05	0.00375	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—IL4—psoriasis	3.06e-05	0.00369	CbGpPWpGaD
Naproxen—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	3.06e-05	0.00368	CbGpPWpGaD
Naproxen—PTGS1—Selenium Micronutrient Network—ICAM1—psoriasis	3.01e-05	0.00363	CbGpPWpGaD
Naproxen—ALB—Vitamin B12 Metabolism—ICAM1—psoriasis	2.99e-05	0.0036	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—HCAR2—psoriasis	2.92e-05	0.00351	CbGpPWpGaD
Naproxen—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—psoriasis	2.86e-05	0.00344	CbGpPWpGaD
Naproxen—Haemoglobin—Methotrexate—psoriasis	2.86e-05	0.000184	CcSEcCtD
Naproxen—Rash—Mycophenolic acid—psoriasis	2.85e-05	0.000184	CcSEcCtD
Naproxen—Dermatitis—Mycophenolic acid—psoriasis	2.85e-05	0.000184	CcSEcCtD
Naproxen—Pain—Prednisolone—psoriasis	2.84e-05	0.000184	CcSEcCtD
Naproxen—Haemorrhage—Methotrexate—psoriasis	2.84e-05	0.000184	CcSEcCtD
Naproxen—Hepatitis—Methotrexate—psoriasis	2.84e-05	0.000184	CcSEcCtD
Naproxen—Urticaria—Mycophenolate mofetil—psoriasis	2.83e-05	0.000183	CcSEcCtD
Naproxen—Headache—Mycophenolic acid—psoriasis	2.83e-05	0.000183	CcSEcCtD
Naproxen—Decreased appetite—Hydrocortisone—psoriasis	2.82e-05	0.000182	CcSEcCtD
Naproxen—Pharyngitis—Methotrexate—psoriasis	2.82e-05	0.000182	CcSEcCtD
Naproxen—Abdominal pain—Mycophenolate mofetil—psoriasis	2.82e-05	0.000182	CcSEcCtD
Naproxen—Body temperature increased—Mycophenolate mofetil—psoriasis	2.82e-05	0.000182	CcSEcCtD
Naproxen—Urinary tract disorder—Methotrexate—psoriasis	2.81e-05	0.000181	CcSEcCtD
Naproxen—Gastrointestinal disorder—Hydrocortisone—psoriasis	2.8e-05	0.000181	CcSEcCtD
Naproxen—Fatigue—Hydrocortisone—psoriasis	2.8e-05	0.000181	CcSEcCtD
Naproxen—Vision blurred—Prednisone—psoriasis	2.79e-05	0.00018	CcSEcCtD
Naproxen—Urethral disorder—Methotrexate—psoriasis	2.79e-05	0.00018	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Triamcinolone—psoriasis	2.79e-05	0.00018	CcSEcCtD
Naproxen—Pain—Hydrocortisone—psoriasis	2.78e-05	0.000179	CcSEcCtD
Naproxen—Oedema—Dexamethasone—psoriasis	2.78e-05	0.000179	CcSEcCtD
Naproxen—Anaphylactic shock—Dexamethasone—psoriasis	2.78e-05	0.000179	CcSEcCtD
Naproxen—Anaphylactic shock—Betamethasone—psoriasis	2.78e-05	0.000179	CcSEcCtD
Naproxen—Oedema—Betamethasone—psoriasis	2.78e-05	0.000179	CcSEcCtD
Naproxen—Insomnia—Triamcinolone—psoriasis	2.77e-05	0.000179	CcSEcCtD
Naproxen—Infection—Dexamethasone—psoriasis	2.76e-05	0.000178	CcSEcCtD
Naproxen—Infection—Betamethasone—psoriasis	2.76e-05	0.000178	CcSEcCtD
Naproxen—Ill-defined disorder—Prednisone—psoriasis	2.75e-05	0.000177	CcSEcCtD
Naproxen—Paraesthesia—Triamcinolone—psoriasis	2.75e-05	0.000177	CcSEcCtD
Naproxen—Feeling abnormal—Prednisolone—psoriasis	2.74e-05	0.000177	CcSEcCtD
Naproxen—Visual impairment—Methotrexate—psoriasis	2.74e-05	0.000177	CcSEcCtD
Naproxen—Anaemia—Prednisone—psoriasis	2.74e-05	0.000177	CcSEcCtD
Naproxen—Shock—Betamethasone—psoriasis	2.73e-05	0.000176	CcSEcCtD
Naproxen—Shock—Dexamethasone—psoriasis	2.73e-05	0.000176	CcSEcCtD
Naproxen—Dyspnoea—Triamcinolone—psoriasis	2.73e-05	0.000176	CcSEcCtD
Naproxen—Nervous system disorder—Betamethasone—psoriasis	2.72e-05	0.000176	CcSEcCtD
Naproxen—Nervous system disorder—Dexamethasone—psoriasis	2.72e-05	0.000176	CcSEcCtD
Naproxen—Thrombocytopenia—Betamethasone—psoriasis	2.72e-05	0.000175	CcSEcCtD
Naproxen—Thrombocytopenia—Dexamethasone—psoriasis	2.72e-05	0.000175	CcSEcCtD
Naproxen—Tachycardia—Dexamethasone—psoriasis	2.71e-05	0.000175	CcSEcCtD
Naproxen—Tachycardia—Betamethasone—psoriasis	2.71e-05	0.000175	CcSEcCtD
Naproxen—Angioedema—Prednisone—psoriasis	2.71e-05	0.000175	CcSEcCtD
Naproxen—Hypersensitivity—Cyclosporine—psoriasis	2.69e-05	0.000174	CcSEcCtD
Naproxen—Dyspepsia—Triamcinolone—psoriasis	2.69e-05	0.000174	CcSEcCtD
Naproxen—Erythema multiforme—Methotrexate—psoriasis	2.69e-05	0.000174	CcSEcCtD
Naproxen—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	2.68e-05	0.00323	CbGpPWpGaD
Naproxen—Nausea—Mycophenolic acid—psoriasis	2.68e-05	0.000173	CcSEcCtD
Naproxen—Hyperhidrosis—Betamethasone—psoriasis	2.68e-05	0.000173	CcSEcCtD
Naproxen—Hyperhidrosis—Dexamethasone—psoriasis	2.68e-05	0.000173	CcSEcCtD
Naproxen—Feeling abnormal—Hydrocortisone—psoriasis	2.68e-05	0.000173	CcSEcCtD
Naproxen—Malaise—Prednisone—psoriasis	2.67e-05	0.000172	CcSEcCtD
Naproxen—Vertigo—Prednisone—psoriasis	2.66e-05	0.000172	CcSEcCtD
Naproxen—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—psoriasis	2.66e-05	0.0032	CbGpPWpGaD
Naproxen—Eye disorder—Methotrexate—psoriasis	2.66e-05	0.000172	CcSEcCtD
Naproxen—Gastrointestinal pain—Hydrocortisone—psoriasis	2.66e-05	0.000171	CcSEcCtD
Naproxen—Syncope—Prednisone—psoriasis	2.66e-05	0.000171	CcSEcCtD
Naproxen—Tinnitus—Methotrexate—psoriasis	2.65e-05	0.000171	CcSEcCtD
Naproxen—ALB—Selenium Micronutrient Network—CAT—psoriasis	2.65e-05	0.00319	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—CRP—psoriasis	2.65e-05	0.00319	CbGpPWpGaD
Naproxen—Anorexia—Dexamethasone—psoriasis	2.65e-05	0.000171	CcSEcCtD
Naproxen—Anorexia—Betamethasone—psoriasis	2.65e-05	0.000171	CcSEcCtD
Naproxen—Urticaria—Prednisolone—psoriasis	2.64e-05	0.000171	CcSEcCtD
Naproxen—Cardiac disorder—Methotrexate—psoriasis	2.64e-05	0.00017	CcSEcCtD
Naproxen—Fatigue—Triamcinolone—psoriasis	2.64e-05	0.00017	CcSEcCtD
Naproxen—Hypersensitivity—Mycophenolate mofetil—psoriasis	2.63e-05	0.00017	CcSEcCtD
Naproxen—Asthenia—Cyclosporine—psoriasis	2.62e-05	0.000169	CcSEcCtD
Naproxen—Pain—Triamcinolone—psoriasis	2.62e-05	0.000169	CcSEcCtD
Naproxen—Loss of consciousness—Prednisone—psoriasis	2.6e-05	0.000168	CcSEcCtD
Naproxen—PTGS2—Selenium Micronutrient Network—CRP—psoriasis	2.6e-05	0.00313	CbGpPWpGaD
Naproxen—Hypotension—Betamethasone—psoriasis	2.59e-05	0.000167	CcSEcCtD
Naproxen—Hypotension—Dexamethasone—psoriasis	2.59e-05	0.000167	CcSEcCtD
Naproxen—Pruritus—Cyclosporine—psoriasis	2.59e-05	0.000167	CcSEcCtD
Naproxen—Urticaria—Hydrocortisone—psoriasis	2.58e-05	0.000167	CcSEcCtD
Naproxen—Angiopathy—Methotrexate—psoriasis	2.58e-05	0.000167	CcSEcCtD
Naproxen—Immune system disorder—Methotrexate—psoriasis	2.57e-05	0.000166	CcSEcCtD
Naproxen—Body temperature increased—Hydrocortisone—psoriasis	2.57e-05	0.000166	CcSEcCtD
Naproxen—Abdominal pain—Hydrocortisone—psoriasis	2.57e-05	0.000166	CcSEcCtD
Naproxen—Convulsion—Prednisone—psoriasis	2.57e-05	0.000166	CcSEcCtD
Naproxen—Mediastinal disorder—Methotrexate—psoriasis	2.56e-05	0.000165	CcSEcCtD
Naproxen—Asthenia—Mycophenolate mofetil—psoriasis	2.56e-05	0.000165	CcSEcCtD
Naproxen—Hypertension—Prednisone—psoriasis	2.56e-05	0.000165	CcSEcCtD
Naproxen—Chills—Methotrexate—psoriasis	2.55e-05	0.000165	CcSEcCtD
Naproxen—PTGS2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	2.54e-05	0.00306	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TAGAP—psoriasis	2.53e-05	0.00305	CbGpPWpGaD
Naproxen—Musculoskeletal discomfort—Dexamethasone—psoriasis	2.53e-05	0.000163	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Betamethasone—psoriasis	2.53e-05	0.000163	CcSEcCtD
Naproxen—Pruritus—Mycophenolate mofetil—psoriasis	2.52e-05	0.000163	CcSEcCtD
Naproxen—Myalgia—Prednisone—psoriasis	2.52e-05	0.000163	CcSEcCtD
Naproxen—Arthralgia—Prednisone—psoriasis	2.52e-05	0.000163	CcSEcCtD
Naproxen—Feeling abnormal—Triamcinolone—psoriasis	2.52e-05	0.000163	CcSEcCtD
Naproxen—Anxiety—Prednisone—psoriasis	2.51e-05	0.000162	CcSEcCtD
Naproxen—Alopecia—Methotrexate—psoriasis	2.51e-05	0.000162	CcSEcCtD
Naproxen—Insomnia—Betamethasone—psoriasis	2.51e-05	0.000162	CcSEcCtD
Naproxen—Insomnia—Dexamethasone—psoriasis	2.51e-05	0.000162	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	2.5e-05	0.000162	CcSEcCtD
Naproxen—Diarrhoea—Cyclosporine—psoriasis	2.5e-05	0.000161	CcSEcCtD
Naproxen—Paraesthesia—Betamethasone—psoriasis	2.49e-05	0.000161	CcSEcCtD
Naproxen—Paraesthesia—Dexamethasone—psoriasis	2.49e-05	0.000161	CcSEcCtD
Naproxen—Discomfort—Prednisone—psoriasis	2.49e-05	0.000161	CcSEcCtD
Naproxen—Mental disorder—Methotrexate—psoriasis	2.49e-05	0.000161	CcSEcCtD
Naproxen—Erythema—Methotrexate—psoriasis	2.47e-05	0.00016	CcSEcCtD
Naproxen—Malnutrition—Methotrexate—psoriasis	2.47e-05	0.00016	CcSEcCtD
Naproxen—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—psoriasis	2.47e-05	0.00298	CbGpPWpGaD
Naproxen—Hypersensitivity—Prednisolone—psoriasis	2.45e-05	0.000158	CcSEcCtD
Naproxen—Dyspepsia—Dexamethasone—psoriasis	2.44e-05	0.000158	CcSEcCtD
Naproxen—Dyspepsia—Betamethasone—psoriasis	2.44e-05	0.000158	CcSEcCtD
Naproxen—UGT2B7—Metabolism—NDUFA5—psoriasis	2.44e-05	0.00294	CbGpPWpGaD
Naproxen—Diarrhoea—Mycophenolate mofetil—psoriasis	2.44e-05	0.000157	CcSEcCtD
Naproxen—ALB—Folate Metabolism—ICAM1—psoriasis	2.43e-05	0.00293	CbGpPWpGaD
Naproxen—Urticaria—Triamcinolone—psoriasis	2.43e-05	0.000157	CcSEcCtD
Naproxen—Body temperature increased—Triamcinolone—psoriasis	2.42e-05	0.000156	CcSEcCtD
Naproxen—Dizziness—Cyclosporine—psoriasis	2.42e-05	0.000156	CcSEcCtD
Naproxen—Anaphylactic shock—Prednisone—psoriasis	2.42e-05	0.000156	CcSEcCtD
Naproxen—Oedema—Prednisone—psoriasis	2.42e-05	0.000156	CcSEcCtD
Naproxen—Decreased appetite—Dexamethasone—psoriasis	2.41e-05	0.000156	CcSEcCtD
Naproxen—Decreased appetite—Betamethasone—psoriasis	2.41e-05	0.000156	CcSEcCtD
Naproxen—Infection—Prednisone—psoriasis	2.4e-05	0.000155	CcSEcCtD
Naproxen—Gastrointestinal disorder—Dexamethasone—psoriasis	2.4e-05	0.000155	CcSEcCtD
Naproxen—Gastrointestinal disorder—Betamethasone—psoriasis	2.4e-05	0.000155	CcSEcCtD
Naproxen—Hypersensitivity—Hydrocortisone—psoriasis	2.39e-05	0.000154	CcSEcCtD
Naproxen—Fatigue—Dexamethasone—psoriasis	2.39e-05	0.000154	CcSEcCtD
Naproxen—Fatigue—Betamethasone—psoriasis	2.39e-05	0.000154	CcSEcCtD
Naproxen—PTGS2—Selenium Micronutrient Network—ICAM1—psoriasis	2.39e-05	0.00288	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—IL4—psoriasis	2.38e-05	0.00286	CbGpPWpGaD
Naproxen—Shock—Prednisone—psoriasis	2.38e-05	0.000153	CcSEcCtD
Naproxen—Pain—Betamethasone—psoriasis	2.37e-05	0.000153	CcSEcCtD
Naproxen—Pain—Dexamethasone—psoriasis	2.37e-05	0.000153	CcSEcCtD
Naproxen—Nervous system disorder—Prednisone—psoriasis	2.37e-05	0.000153	CcSEcCtD
Naproxen—Tachycardia—Prednisone—psoriasis	2.36e-05	0.000152	CcSEcCtD
Naproxen—Dizziness—Mycophenolate mofetil—psoriasis	2.36e-05	0.000152	CcSEcCtD
Naproxen—Skin disorder—Prednisone—psoriasis	2.35e-05	0.000152	CcSEcCtD
Naproxen—Hyperhidrosis—Prednisone—psoriasis	2.34e-05	0.000151	CcSEcCtD
Naproxen—Vision blurred—Methotrexate—psoriasis	2.33e-05	0.000151	CcSEcCtD
Naproxen—Asthenia—Hydrocortisone—psoriasis	2.33e-05	0.00015	CcSEcCtD
Naproxen—Vomiting—Cyclosporine—psoriasis	2.32e-05	0.00015	CcSEcCtD
Naproxen—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	2.31e-05	0.00278	CbGpPWpGaD
Naproxen—Rash—Cyclosporine—psoriasis	2.3e-05	0.000149	CcSEcCtD
Naproxen—Anorexia—Prednisone—psoriasis	2.3e-05	0.000149	CcSEcCtD
Naproxen—Dermatitis—Cyclosporine—psoriasis	2.3e-05	0.000149	CcSEcCtD
Naproxen—Pruritus—Hydrocortisone—psoriasis	2.3e-05	0.000148	CcSEcCtD
Naproxen—Ill-defined disorder—Methotrexate—psoriasis	2.3e-05	0.000148	CcSEcCtD
Naproxen—PTGS1—Selenium Micronutrient Network—IFNG—psoriasis	2.29e-05	0.00276	CbGpPWpGaD
Naproxen—Headache—Cyclosporine—psoriasis	2.29e-05	0.000148	CcSEcCtD
Naproxen—Anaemia—Methotrexate—psoriasis	2.29e-05	0.000148	CcSEcCtD
Naproxen—Feeling abnormal—Dexamethasone—psoriasis	2.29e-05	0.000148	CcSEcCtD
Naproxen—Feeling abnormal—Betamethasone—psoriasis	2.29e-05	0.000148	CcSEcCtD
Naproxen—ALB—Vitamin B12 Metabolism—IFNG—psoriasis	2.28e-05	0.00274	CbGpPWpGaD
Naproxen—Gastrointestinal pain—Betamethasone—psoriasis	2.27e-05	0.000146	CcSEcCtD
Naproxen—Gastrointestinal pain—Dexamethasone—psoriasis	2.27e-05	0.000146	CcSEcCtD
Naproxen—Vomiting—Mycophenolate mofetil—psoriasis	2.27e-05	0.000146	CcSEcCtD
Naproxen—Hypersensitivity—Triamcinolone—psoriasis	2.25e-05	0.000145	CcSEcCtD
Naproxen—Rash—Mycophenolate mofetil—psoriasis	2.25e-05	0.000145	CcSEcCtD
Naproxen—Dermatitis—Mycophenolate mofetil—psoriasis	2.25e-05	0.000145	CcSEcCtD
Naproxen—Headache—Mycophenolate mofetil—psoriasis	2.23e-05	0.000144	CcSEcCtD
Naproxen—Malaise—Methotrexate—psoriasis	2.23e-05	0.000144	CcSEcCtD
Naproxen—Vertigo—Methotrexate—psoriasis	2.22e-05	0.000144	CcSEcCtD
Naproxen—Diarrhoea—Hydrocortisone—psoriasis	2.22e-05	0.000143	CcSEcCtD
Naproxen—Leukopenia—Methotrexate—psoriasis	2.22e-05	0.000143	CcSEcCtD
Naproxen—Urticaria—Dexamethasone—psoriasis	2.2e-05	0.000142	CcSEcCtD
Naproxen—Urticaria—Betamethasone—psoriasis	2.2e-05	0.000142	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Prednisone—psoriasis	2.2e-05	0.000142	CcSEcCtD
Naproxen—Dizziness—Prednisolone—psoriasis	2.2e-05	0.000142	CcSEcCtD
Naproxen—Asthenia—Triamcinolone—psoriasis	2.19e-05	0.000142	CcSEcCtD
Naproxen—Abdominal pain—Dexamethasone—psoriasis	2.19e-05	0.000142	CcSEcCtD
Naproxen—Body temperature increased—Betamethasone—psoriasis	2.19e-05	0.000142	CcSEcCtD
Naproxen—Abdominal pain—Betamethasone—psoriasis	2.19e-05	0.000142	CcSEcCtD
Naproxen—Body temperature increased—Dexamethasone—psoriasis	2.19e-05	0.000142	CcSEcCtD
Naproxen—Insomnia—Prednisone—psoriasis	2.19e-05	0.000141	CcSEcCtD
Naproxen—Nausea—Cyclosporine—psoriasis	2.17e-05	0.00014	CcSEcCtD
Naproxen—Paraesthesia—Prednisone—psoriasis	2.17e-05	0.00014	CcSEcCtD
Naproxen—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—psoriasis	2.17e-05	0.00261	CbGpPWpGaD
Naproxen—Pruritus—Triamcinolone—psoriasis	2.16e-05	0.00014	CcSEcCtD
Naproxen—Cough—Methotrexate—psoriasis	2.16e-05	0.000139	CcSEcCtD
Naproxen—Dizziness—Hydrocortisone—psoriasis	2.15e-05	0.000139	CcSEcCtD
Naproxen—Convulsion—Methotrexate—psoriasis	2.14e-05	0.000138	CcSEcCtD
Naproxen—Dyspepsia—Prednisone—psoriasis	2.13e-05	0.000137	CcSEcCtD
Naproxen—SLCO1A2—Metabolism—NDUFA5—psoriasis	2.12e-05	0.00256	CbGpPWpGaD
Naproxen—Nausea—Mycophenolate mofetil—psoriasis	2.12e-05	0.000137	CcSEcCtD
Naproxen—Chest pain—Methotrexate—psoriasis	2.11e-05	0.000136	CcSEcCtD
Naproxen—Arthralgia—Methotrexate—psoriasis	2.11e-05	0.000136	CcSEcCtD
Naproxen—Myalgia—Methotrexate—psoriasis	2.11e-05	0.000136	CcSEcCtD
Naproxen—ALB—Selenium Micronutrient Network—CRP—psoriasis	2.1e-05	0.00253	CbGpPWpGaD
Naproxen—Decreased appetite—Prednisone—psoriasis	2.1e-05	0.000136	CcSEcCtD
Naproxen—Rash—Prednisolone—psoriasis	2.1e-05	0.000135	CcSEcCtD
Naproxen—Dermatitis—Prednisolone—psoriasis	2.1e-05	0.000135	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	2.09e-05	0.000135	CcSEcCtD
Naproxen—Fatigue—Prednisone—psoriasis	2.08e-05	0.000135	CcSEcCtD
Naproxen—Headache—Prednisolone—psoriasis	2.08e-05	0.000134	CcSEcCtD
Naproxen—Discomfort—Methotrexate—psoriasis	2.08e-05	0.000134	CcSEcCtD
Naproxen—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	2.08e-05	0.00251	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—CYP2S1—psoriasis	2.07e-05	0.0025	CbGpPWpGaD
Naproxen—Constipation—Prednisone—psoriasis	2.07e-05	0.000133	CcSEcCtD
Naproxen—Vomiting—Hydrocortisone—psoriasis	2.07e-05	0.000133	CcSEcCtD
Naproxen—Rash—Hydrocortisone—psoriasis	2.05e-05	0.000132	CcSEcCtD
Naproxen—Dermatitis—Hydrocortisone—psoriasis	2.05e-05	0.000132	CcSEcCtD
Naproxen—Confusional state—Methotrexate—psoriasis	2.04e-05	0.000131	CcSEcCtD
Naproxen—Headache—Hydrocortisone—psoriasis	2.03e-05	0.000131	CcSEcCtD
Naproxen—Dizziness—Triamcinolone—psoriasis	2.02e-05	0.000131	CcSEcCtD
Naproxen—Anaphylactic shock—Methotrexate—psoriasis	2.02e-05	0.00013	CcSEcCtD
Naproxen—PTGS2—Spinal Cord Injury—LEP—psoriasis	2.01e-05	0.00242	CbGpPWpGaD
Naproxen—Infection—Methotrexate—psoriasis	2.01e-05	0.00013	CcSEcCtD
Naproxen—Feeling abnormal—Prednisone—psoriasis	1.99e-05	0.000129	CcSEcCtD
Naproxen—Asthenia—Dexamethasone—psoriasis	1.99e-05	0.000129	CcSEcCtD
Naproxen—Asthenia—Betamethasone—psoriasis	1.99e-05	0.000129	CcSEcCtD
Naproxen—UGT1A1—Metabolism—NDUFA5—psoriasis	1.98e-05	0.00239	CbGpPWpGaD
Naproxen—Nervous system disorder—Methotrexate—psoriasis	1.98e-05	0.000128	CcSEcCtD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.98e-05	0.00238	CbGpPWpGaD
Naproxen—PTGS2—Aryl Hydrocarbon Receptor—TNF—psoriasis	1.98e-05	0.00238	CbGpPWpGaD
Naproxen—Thrombocytopenia—Methotrexate—psoriasis	1.98e-05	0.000128	CcSEcCtD
Naproxen—Gastrointestinal pain—Prednisone—psoriasis	1.98e-05	0.000128	CcSEcCtD
Naproxen—Nausea—Prednisolone—psoriasis	1.98e-05	0.000128	CcSEcCtD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—CP—psoriasis	1.97e-05	0.00238	CbGpPWpGaD
Naproxen—Pruritus—Betamethasone—psoriasis	1.96e-05	0.000127	CcSEcCtD
Naproxen—Pruritus—Dexamethasone—psoriasis	1.96e-05	0.000127	CcSEcCtD
Naproxen—Skin disorder—Methotrexate—psoriasis	1.96e-05	0.000127	CcSEcCtD
Naproxen—Hyperhidrosis—Methotrexate—psoriasis	1.95e-05	0.000126	CcSEcCtD
Naproxen—Vomiting—Triamcinolone—psoriasis	1.94e-05	0.000126	CcSEcCtD
Naproxen—ALB—Selenium Micronutrient Network—ICAM1—psoriasis	1.93e-05	0.00233	CbGpPWpGaD
Naproxen—Nausea—Hydrocortisone—psoriasis	1.93e-05	0.000125	CcSEcCtD
Naproxen—Rash—Triamcinolone—psoriasis	1.93e-05	0.000124	CcSEcCtD
Naproxen—Dermatitis—Triamcinolone—psoriasis	1.93e-05	0.000124	CcSEcCtD
Naproxen—Anorexia—Methotrexate—psoriasis	1.93e-05	0.000124	CcSEcCtD
Naproxen—Urticaria—Prednisone—psoriasis	1.92e-05	0.000124	CcSEcCtD
Naproxen—Headache—Triamcinolone—psoriasis	1.92e-05	0.000124	CcSEcCtD
Naproxen—Abdominal pain—Prednisone—psoriasis	1.91e-05	0.000123	CcSEcCtD
Naproxen—Body temperature increased—Prednisone—psoriasis	1.91e-05	0.000123	CcSEcCtD
Naproxen—PTGS1—Selenium Micronutrient Network—NFKB1—psoriasis	1.91e-05	0.0023	CbGpPWpGaD
Naproxen—Diarrhoea—Dexamethasone—psoriasis	1.9e-05	0.000123	CcSEcCtD
Naproxen—Diarrhoea—Betamethasone—psoriasis	1.9e-05	0.000123	CcSEcCtD
Naproxen—ALB—SLC-mediated transmembrane transport—CP—psoriasis	1.9e-05	0.00229	CbGpPWpGaD
Naproxen—ALB—Vitamin B12 Metabolism—NFKB1—psoriasis	1.89e-05	0.00228	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—ICAM1—psoriasis	1.89e-05	0.00228	CbGpPWpGaD
Naproxen—Hypotension—Methotrexate—psoriasis	1.89e-05	0.000122	CcSEcCtD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—CARM1—psoriasis	1.88e-05	0.00227	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—NOS2—psoriasis	1.88e-05	0.00226	CbGpPWpGaD
Naproxen—SLC22A6—Transmembrane transport of small molecules—CP—psoriasis	1.86e-05	0.00223	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—IFNG—psoriasis	1.85e-05	0.00223	CbGpPWpGaD
Naproxen—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriasis	1.85e-05	0.00223	CbGpPWpGaD
Naproxen—Musculoskeletal discomfort—Methotrexate—psoriasis	1.84e-05	0.000119	CcSEcCtD
Naproxen—Dizziness—Dexamethasone—psoriasis	1.84e-05	0.000118	CcSEcCtD
Naproxen—Dizziness—Betamethasone—psoriasis	1.84e-05	0.000118	CcSEcCtD
Naproxen—Insomnia—Methotrexate—psoriasis	1.83e-05	0.000118	CcSEcCtD
Naproxen—PTGS2—C-MYB transcription factor network—CD4—psoriasis	1.82e-05	0.0022	CbGpPWpGaD
Naproxen—PTGS2—Selenium Micronutrient Network—IFNG—psoriasis	1.82e-05	0.00219	CbGpPWpGaD
Naproxen—Nausea—Triamcinolone—psoriasis	1.82e-05	0.000117	CcSEcCtD
Naproxen—Paraesthesia—Methotrexate—psoriasis	1.81e-05	0.000117	CcSEcCtD
Naproxen—SLCO1A2—Metabolism—CYP2S1—psoriasis	1.81e-05	0.00217	CbGpPWpGaD
Naproxen—Dyspnoea—Methotrexate—psoriasis	1.8e-05	0.000116	CcSEcCtD
Naproxen—Somnolence—Methotrexate—psoriasis	1.8e-05	0.000116	CcSEcCtD
Naproxen—Hypersensitivity—Prednisone—psoriasis	1.78e-05	0.000115	CcSEcCtD
Naproxen—Dyspepsia—Methotrexate—psoriasis	1.78e-05	0.000115	CcSEcCtD
Naproxen—SLC22A6—Transmembrane transport of small molecules—CARM1—psoriasis	1.77e-05	0.00213	CbGpPWpGaD
Naproxen—Vomiting—Dexamethasone—psoriasis	1.76e-05	0.000114	CcSEcCtD
Naproxen—Vomiting—Betamethasone—psoriasis	1.76e-05	0.000114	CcSEcCtD
Naproxen—Decreased appetite—Methotrexate—psoriasis	1.76e-05	0.000113	CcSEcCtD
Naproxen—Rash—Betamethasone—psoriasis	1.75e-05	0.000113	CcSEcCtD
Naproxen—Rash—Dexamethasone—psoriasis	1.75e-05	0.000113	CcSEcCtD
Naproxen—Dermatitis—Betamethasone—psoriasis	1.75e-05	0.000113	CcSEcCtD
Naproxen—Dermatitis—Dexamethasone—psoriasis	1.75e-05	0.000113	CcSEcCtD
Naproxen—Gastrointestinal disorder—Methotrexate—psoriasis	1.74e-05	0.000113	CcSEcCtD
Naproxen—Fatigue—Methotrexate—psoriasis	1.74e-05	0.000112	CcSEcCtD
Naproxen—Headache—Dexamethasone—psoriasis	1.74e-05	0.000112	CcSEcCtD
Naproxen—Headache—Betamethasone—psoriasis	1.74e-05	0.000112	CcSEcCtD
Naproxen—Asthenia—Prednisone—psoriasis	1.73e-05	0.000112	CcSEcCtD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	1.73e-05	0.00208	CbGpPWpGaD
Naproxen—Pain—Methotrexate—psoriasis	1.73e-05	0.000111	CcSEcCtD
Naproxen—Pruritus—Prednisone—psoriasis	1.71e-05	0.00011	CcSEcCtD
Naproxen—UGT1A1—Metabolism—CYP2S1—psoriasis	1.69e-05	0.00203	CbGpPWpGaD
Naproxen—Feeling abnormal—Methotrexate—psoriasis	1.66e-05	0.000107	CcSEcCtD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.65e-05	0.00199	CbGpPWpGaD
Naproxen—Diarrhoea—Prednisone—psoriasis	1.65e-05	0.000107	CcSEcCtD
Naproxen—Gastrointestinal pain—Methotrexate—psoriasis	1.65e-05	0.000107	CcSEcCtD
Naproxen—Nausea—Betamethasone—psoriasis	1.65e-05	0.000106	CcSEcCtD
Naproxen—Nausea—Dexamethasone—psoriasis	1.65e-05	0.000106	CcSEcCtD
Naproxen—PTGS1—Metabolism—NDUFA5—psoriasis	1.62e-05	0.00195	CbGpPWpGaD
Naproxen—Urticaria—Methotrexate—psoriasis	1.6e-05	0.000104	CcSEcCtD
Naproxen—Dizziness—Prednisone—psoriasis	1.6e-05	0.000103	CcSEcCtD
Naproxen—Body temperature increased—Methotrexate—psoriasis	1.6e-05	0.000103	CcSEcCtD
Naproxen—Abdominal pain—Methotrexate—psoriasis	1.6e-05	0.000103	CcSEcCtD
Naproxen—AKR1C3—Metabolism—CARM1—psoriasis	1.54e-05	0.00186	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—NFKB1—psoriasis	1.54e-05	0.00186	CbGpPWpGaD
Naproxen—Vomiting—Prednisone—psoriasis	1.54e-05	9.92e-05	CcSEcCtD
Naproxen—Rash—Prednisone—psoriasis	1.52e-05	9.84e-05	CcSEcCtD
Naproxen—Dermatitis—Prednisone—psoriasis	1.52e-05	9.83e-05	CcSEcCtD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	1.52e-05	0.00183	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CCL20—psoriasis	1.52e-05	0.00183	CbGpPWpGaD
Naproxen—Headache—Prednisone—psoriasis	1.51e-05	9.77e-05	CcSEcCtD
Naproxen—PTGS2—Selenium Micronutrient Network—NFKB1—psoriasis	1.51e-05	0.00182	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.51e-05	0.00181	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	1.49e-05	0.0018	CbGpPWpGaD
Naproxen—Hypersensitivity—Methotrexate—psoriasis	1.49e-05	9.61e-05	CcSEcCtD
Naproxen—PTGS1—Selenium Micronutrient Network—TNF—psoriasis	1.48e-05	0.00179	CbGpPWpGaD
Naproxen—ALB—Vitamin B12 Metabolism—TNF—psoriasis	1.47e-05	0.00177	CbGpPWpGaD
Naproxen—ALB—Selenium Micronutrient Network—IFNG—psoriasis	1.47e-05	0.00177	CbGpPWpGaD
Naproxen—Asthenia—Methotrexate—psoriasis	1.45e-05	9.35e-05	CcSEcCtD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.44e-05	0.00174	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	1.44e-05	0.00173	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—IFNG—psoriasis	1.44e-05	0.00173	CbGpPWpGaD
Naproxen—Nausea—Prednisone—psoriasis	1.44e-05	9.27e-05	CcSEcCtD
Naproxen—Pruritus—Methotrexate—psoriasis	1.43e-05	9.22e-05	CcSEcCtD
Naproxen—Diarrhoea—Methotrexate—psoriasis	1.38e-05	8.92e-05	CcSEcCtD
Naproxen—PTGS1—Metabolism—CYP2S1—psoriasis	1.37e-05	0.00165	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—CXCL8—psoriasis	1.34e-05	0.00161	CbGpPWpGaD
Naproxen—Dizziness—Methotrexate—psoriasis	1.34e-05	8.62e-05	CcSEcCtD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	1.31e-05	0.00157	CbGpPWpGaD
Naproxen—Vomiting—Methotrexate—psoriasis	1.28e-05	8.29e-05	CcSEcCtD
Naproxen—PTGS2—Metabolism—NDUFA5—psoriasis	1.28e-05	0.00154	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	1.28e-05	0.00154	CbGpPWpGaD
Naproxen—Rash—Methotrexate—psoriasis	1.27e-05	8.22e-05	CcSEcCtD
Naproxen—Dermatitis—Methotrexate—psoriasis	1.27e-05	8.21e-05	CcSEcCtD
Naproxen—Headache—Methotrexate—psoriasis	1.27e-05	8.17e-05	CcSEcCtD
Naproxen—ALB—Selenium Micronutrient Network—NFKB1—psoriasis	1.22e-05	0.00147	CbGpPWpGaD
Naproxen—Nausea—Methotrexate—psoriasis	1.2e-05	7.74e-05	CcSEcCtD
Naproxen—ALB—Platelet degranulation—VEGFA—psoriasis	1.2e-05	0.00144	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—TNF—psoriasis	1.2e-05	0.00144	CbGpPWpGaD
Naproxen—PTGS1—Selenium Micronutrient Network—IL6—psoriasis	1.2e-05	0.00144	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.2e-05	0.00144	CbGpPWpGaD
Naproxen—ALB—Vitamin B12 Metabolism—IL6—psoriasis	1.19e-05	0.00143	CbGpPWpGaD
Naproxen—PTGS2—Selenium Micronutrient Network—TNF—psoriasis	1.18e-05	0.00142	CbGpPWpGaD
Naproxen—ALB—Hemostasis—ITGAL—psoriasis	1.15e-05	0.00139	CbGpPWpGaD
Naproxen—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	1.14e-05	0.00138	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	1.12e-05	0.00135	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	1.12e-05	0.00135	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CYP2S1—psoriasis	1.09e-05	0.00131	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—TP53—psoriasis	1.06e-05	0.00127	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—NDUFA5—psoriasis	1.04e-05	0.00126	CbGpPWpGaD
Naproxen—ALB—Metabolism—NDUFA5—psoriasis	1.04e-05	0.00125	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—CARM1—psoriasis	1.01e-05	0.00122	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	9.73e-06	0.00117	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—CARM1—psoriasis	9.68e-06	0.00117	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—IL6—psoriasis	9.67e-06	0.00116	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—CP—psoriasis	9.65e-06	0.00116	CbGpPWpGaD
Naproxen—ALB—Selenium Micronutrient Network—TNF—psoriasis	9.52e-06	0.00115	CbGpPWpGaD
Naproxen—PTGS2—Selenium Micronutrient Network—IL6—psoriasis	9.5e-06	0.00114	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—CAT—psoriasis	9.48e-06	0.00114	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.47e-06	0.00114	CbGpPWpGaD
Naproxen—AKR1C3—Disease—HLA-A—psoriasis	9.42e-06	0.00113	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—TNF—psoriasis	9.31e-06	0.00112	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—CARM1—psoriasis	9.2e-06	0.00111	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CYP2S1—psoriasis	8.88e-06	0.00107	CbGpPWpGaD
Naproxen—ALB—Metabolism—CYP2S1—psoriasis	8.83e-06	0.00106	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—CARM1—psoriasis	8.82e-06	0.00106	CbGpPWpGaD
Naproxen—AKR1C3—Disease—APOE—psoriasis	8.8e-06	0.00106	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—NDUFA5—psoriasis	8.5e-06	0.00102	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	8.46e-06	0.00102	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—SOCS1—psoriasis	8.35e-06	0.00101	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.25e-06	0.000993	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—CARM1—psoriasis	8.23e-06	0.000991	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—TP53—psoriasis	8.21e-06	0.000988	CbGpPWpGaD
Naproxen—AKR1C3—Disease—NOS2—psoriasis	8.2e-06	0.000987	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	8.14e-06	0.00098	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	7.92e-06	0.000954	CbGpPWpGaD
Naproxen—ALB—Selenium Micronutrient Network—IL6—psoriasis	7.69e-06	0.000925	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—IL6—psoriasis	7.51e-06	0.000905	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	7.39e-06	0.00089	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—APOE—psoriasis	7.37e-06	0.000887	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—NDUFA5—psoriasis	7.26e-06	0.000874	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CYP2S1—psoriasis	7.22e-06	0.00087	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.2e-06	0.000867	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	6.77e-06	0.000815	CbGpPWpGaD
Naproxen—AKR1C3—Disease—TYK2—psoriasis	6.71e-06	0.000808	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—CARM1—psoriasis	6.71e-06	0.000808	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PPARG—psoriasis	6.42e-06	0.000773	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	6.33e-06	0.000762	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.27e-06	0.000755	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—CAT—psoriasis	6.23e-06	0.00075	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CYP2S1—psoriasis	6.17e-06	0.000743	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—LEP—psoriasis	6.16e-06	0.000742	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—APOE—psoriasis	6.16e-06	0.000742	CbGpPWpGaD
Naproxen—AKR1C3—Disease—CD4—psoriasis	6.07e-06	0.000731	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—NFKBIA—psoriasis	5.74e-06	0.000691	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—APOE—psoriasis	5.72e-06	0.000688	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	5.58e-06	0.000672	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—CAT—psoriasis	5.43e-06	0.000653	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CARM1—psoriasis	5.33e-06	0.000641	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—VEGFA—psoriasis	5.32e-06	0.00064	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—CAT—psoriasis	5.06e-06	0.00061	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.98e-06	0.0006	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—APOE—psoriasis	4.84e-06	0.000583	CbGpPWpGaD
Naproxen—ALB—Hemostasis—NOS2—psoriasis	4.73e-06	0.00057	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TYK2—psoriasis	4.7e-06	0.000566	CbGpPWpGaD
Naproxen—AKR1C3—Disease—STAT3—psoriasis	4.7e-06	0.000566	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	4.65e-06	0.00056	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—APOE—psoriasis	4.63e-06	0.000557	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CARM1—psoriasis	4.33e-06	0.000522	CbGpPWpGaD
Naproxen—ALB—Metabolism—CARM1—psoriasis	4.31e-06	0.000519	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PPARG—psoriasis	4.22e-06	0.000508	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—APOE—psoriasis	4.22e-06	0.000508	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—CAT—psoriasis	4.13e-06	0.000497	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CXCL8—psoriasis	4.09e-06	0.000493	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.05e-06	0.000488	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.03e-06	0.000485	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—APOE—psoriasis	3.93e-06	0.000474	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—JUN—psoriasis	3.81e-06	0.000458	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.79e-06	0.000456	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PPARG—psoriasis	3.67e-06	0.000442	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—NFKB1—psoriasis	3.66e-06	0.000441	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CARM1—psoriasis	3.53e-06	0.000425	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PPARG—psoriasis	3.43e-06	0.000413	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—VEGFA—psoriasis	3.33e-06	0.0004	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.3e-06	0.000397	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—STAT3—psoriasis	3.29e-06	0.000396	CbGpPWpGaD
Naproxen—AKR1C3—Disease—IL6—psoriasis	3.28e-06	0.000395	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CAT—psoriasis	3.28e-06	0.000395	CbGpPWpGaD
Naproxen—PTGS2—Disease—HLA-A—psoriasis	3.26e-06	0.000392	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.24e-06	0.00039	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—APOE—psoriasis	3.21e-06	0.000386	CbGpPWpGaD
Naproxen—PTGS2—Disease—APOE—psoriasis	3.04e-06	0.000366	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CARM1—psoriasis	3.01e-06	0.000363	CbGpPWpGaD
Naproxen—PTGS2—Disease—NOS2—psoriasis	2.83e-06	0.000341	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.82e-06	0.000339	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PPARG—psoriasis	2.79e-06	0.000336	CbGpPWpGaD
Naproxen—ALB—Hemostasis—VEGFA—psoriasis	2.74e-06	0.00033	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CAT—psoriasis	2.67e-06	0.000321	CbGpPWpGaD
Naproxen—ALB—Metabolism—CAT—psoriasis	2.65e-06	0.000319	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—APOE—psoriasis	2.55e-06	0.000307	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TP53—psoriasis	2.51e-06	0.000303	CbGpPWpGaD
Naproxen—PTGS2—Disease—TYK2—psoriasis	2.32e-06	0.000279	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—IL6—psoriasis	2.3e-06	0.000277	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PPARG—psoriasis	2.22e-06	0.000267	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CAT—psoriasis	2.17e-06	0.000261	CbGpPWpGaD
Naproxen—PTGS2—Disease—CD4—psoriasis	2.1e-06	0.000253	CbGpPWpGaD
Naproxen—ALB—Hemostasis—TP53—psoriasis	2.07e-06	0.000249	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—APOE—psoriasis	2.07e-06	0.000249	CbGpPWpGaD
Naproxen—ALB—Metabolism—APOE—psoriasis	2.06e-06	0.000248	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CAT—psoriasis	1.85e-06	0.000223	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PPARG—psoriasis	1.8e-06	0.000217	CbGpPWpGaD
Naproxen—ALB—Metabolism—PPARG—psoriasis	1.79e-06	0.000216	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—APOE—psoriasis	1.69e-06	0.000203	CbGpPWpGaD
Naproxen—PTGS2—Disease—STAT3—psoriasis	1.62e-06	0.000196	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PPARG—psoriasis	1.47e-06	0.000177	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—APOE—psoriasis	1.44e-06	0.000173	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PPARG—psoriasis	1.25e-06	0.000151	CbGpPWpGaD
Naproxen—PTGS2—Disease—IL6—psoriasis	1.13e-06	0.000137	CbGpPWpGaD
